Study shows potential for new radiopharmaceutical cancer treatment

by Elizabeth Chapin,University of KentuckyGastrin- releasing peptide receptor (GRPR) immunoreactivity in uterine cervix cancer. Hematoxylin and eosin (H&E) staining of uterine cervix cancer

Updated on: February 20,2024 16

Study shows potential for new radiopharmaceutical cancer treatment

by Elizabeth Chapin,University of KentuckyGastrin- releasing peptide receptor (GRPR) immunoreactivity in uterine cervix cancer. Hematoxylin and eosin (H&E) staining of uterine cervix cancer

Updated on:February 20,2024 16

Trial shows promise for new antibody cancer treatment

byKing's College LondonMechanism of cytotoxicity mediated by MOv18 IgE. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-39679-9The first ever clinical trial of a new

Updated on: January 04,2024 10

Trial shows promise for new antibody cancer treatment

byKing's College LondonMechanism of cytotoxicity mediated by MOv18 IgE. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-39679-9The first ever clinical trial of a new

Updated on:January 04,2024 10

Tumor cells' response to chemotherapy is driven by randomness, shows study

byGarvan Institute of Medical ResearchNeuroblastoma cells (cyan) growing as a tumour and the surrounding collagen matrix (magenta). The cells are expressing a biosensor (JNK-KTR) that reads out

Updated on: January 23,2024 18

Tumor cells' response to chemotherapy is driven by randomness, shows study

byGarvan Institute of Medical ResearchNeuroblastoma cells (cyan) growing as a tumour and the surrounding collagen matrix (magenta). The cells are expressing a biosensor (JNK-KTR) that reads out

Updated on:January 23,2024 18

New therapeutic strategy for metastatic prostate cancer patients resistant to standard treatment

FEBRUARY 2, 2024 Editors' notesby Germans Trias i Pujol Research InstituteCredit: Unsplash/CC0 Public DomainA team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and

Updated on: March 15,2024 8

New therapeutic strategy for metastatic prostate cancer patients resistant to standard treatment

FEBRUARY 2, 2024 Editors' notesby Germans Trias i Pujol Research InstituteCredit: Unsplash/CC0 Public DomainA team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and

Updated on:March 15,2024 8

Researchers develop new open-source method to improve decoding of single-cell data

by Ian Demsky,Memorial Sloan Kettering Cancer CenterSpectra uses gene sets and cell types to guide gene program discovery from scRNA-seq data.a, As input, Spectra receives a gene expressio

Updated on: June 11,2024 6

Researchers develop new open-source method to improve decoding of single-cell data

by Ian Demsky,Memorial Sloan Kettering Cancer CenterSpectra uses gene sets and cell types to guide gene program discovery from scRNA-seq data.a, As input, Spectra receives a gene expressio

Updated on:June 11,2024 6

Study: Vitamin D may play a role in prostate cancer disparities

by Cedars-Sinai Medical CenterCredit: CC0 Public DomainVitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with Euro

Updated on: January 30,2024 17

Study: Vitamin D may play a role in prostate cancer disparities

by Cedars-Sinai Medical CenterCredit: CC0 Public DomainVitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with Euro

Updated on:January 30,2024 17

Preventing 'chemo brain' with antioxidants targeting the spinal fluid

by Children's Hospital BostonGraphical abstract. Credit:Neuron(2022). DOI: 10.1016/j.neuron.2022.08.009Up to three quarters of patients receiving cancer chemotherapy suffer from &

Updated on: February 01,2024 12

Preventing 'chemo brain' with antioxidants targeting the spinal fluid

by Children's Hospital BostonGraphical abstract. Credit:Neuron(2022). DOI: 10.1016/j.neuron.2022.08.009Up to three quarters of patients receiving cancer chemotherapy suffer from &

Updated on:February 01,2024 12

Researchers find less risky way to monitor breast cancer progression

by CU Anschutz Medical CampusSchematic for identifying subset of binding sites with TF footprints. (A) When TFs or nucleosomes are bound at TFBSs, they protect different lengths of DNA from nucle

Updated on: February 20,2024 11

Researchers find less risky way to monitor breast cancer progression

by CU Anschutz Medical CampusSchematic for identifying subset of binding sites with TF footprints. (A) When TFs or nucleosomes are bound at TFBSs, they protect different lengths of DNA from nucle

Updated on:February 20,2024 11

BCMA+ EV levels correlate with myeloma response to belantamab-mafodotin

by Impact Journals LLCPatient examples of inverse correlation of BCMA and FLC changes during course of therapy. Credit: 2023 Springer et al.A new research paper was published inOncotarget, entit

Updated on: January 26,2024 19

BCMA+ EV levels correlate with myeloma response to belantamab-mafodotin

by Impact Journals LLCPatient examples of inverse correlation of BCMA and FLC changes during course of therapy. Credit: 2023 Springer et al.A new research paper was published inOncotarget, entit

Updated on:January 26,2024 19

Researchers identify promising drug to treat gastrointestinal cancers

by Joe Dangor,Mayo ClinicCredit: Unsplash/CC0 Public DomainGastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcome

Updated on: April 07,2024 11

Researchers identify promising drug to treat gastrointestinal cancers

by Joe Dangor,Mayo ClinicCredit: Unsplash/CC0 Public DomainGastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcome

Updated on:April 07,2024 11

Imaging after one week on pembrolizumab may predict treatment response in advanced melanoma

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainImaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather tha

Updated on: May 06,2024 16

Imaging after one week on pembrolizumab may predict treatment response in advanced melanoma

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainImaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather tha

Updated on:May 06,2024 16

Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled &quot

Updated on: May 07,2024 13

Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled &quot

Updated on:May 07,2024 13